Bissey P A et al confirmed that the dysregulation of miR‐449b alters the TGF‐β pathway to induce cisplatin resistance by targeting TGFBI in NPC.24 Moreover, chemoradiotherapy‐treated patients with NPC and high miR‐449b levels showed an inferior 5‐year overall survival to those of low‐miR‐449b‐expressing patients (72.8% vs 91.8%, P = .017). The gene discussed is TGFBI; the disease is nasopharyngeal carcinoma.